Abstract
To investigate how overexpression of MAD, an antagonist of MYC oncogenes influences the malignant phenotype of human cancer cells, an adenovirus vector system was used to transfer the human MAD gene (AdMAD) into human astrocytoma cells. Decreased growth potential of AdMAD-infected cells was evidenced by a decrease in [3H]thymidine incorporation, an increase in cell doubling time and alteration of cell-cycle distribution. Diminished malignant potential of AdMAD-infected cells was manifested by their loss of anchorage-independent growth in soft agar and by their inability, in general, to induce tumorigenesis in a xenograft animal model. These studies indicate that adenovirus constructs encoding MAD dramatically inhibit the proliferation and tumorigenicity of human astrocytoma cells and support the use of MAD for gene therapy of human tumours.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alt, F. et al. The human myc-gene family. Cold Spring Harbor Symp. quant Biol. 51, 9–941 (1986).
Kelly, K. & Siebenlist, U. The regulation and expression of c-myc in normal and malignant cells. Annu. Rev. Immun. 4, 317–338 (1986).
DePinho, R., Schreiber-Agus, N. & Alt, F.W. Myc family oncogenes in the development of normal and neoplastic cells. Adv. Cancer Res. 57, 1–46 (1991).
Stern, D., Roberts, A., Roche, N., Sporten, M. & Weinberg, R. Differential responsiveness of myc and ras transfected ceils to growth factors: Selective stimulation of myc transfected cells by epidermal growth factor. Molec. cell. Biol. 6, 870–877 (1986).
Shichiri, M., Hanson, K. & Sedivy, J. Effects of c-myc expression on proliferation, quiescence, and the G0 to Gl transition in nontransformed cells. Cell Growth Differ. 4, 93–104 (1993).
Kohl, N. & Ruley, H.R. Role of c-myc in the transformation of REF52 cells by viral and cellular oncogenes. Oncogene 2, 41–48 (1987).
Heikkila, R. et al. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress into G0 to G1 . Nature 328, 445–449 (1987).
Blackwood, E. & Eisenman, R. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA binding complex with myc. Science 251, 1211–1217 (1991).
Blackwell, T.K., Kretzner, L., Blackwood, E.M., Eisenman, R.N. & Weintraub, H. Sequence-specific DNA binding by the c-Myc protein. Science 250, 1149–1151 (1990).
Prendergast, G.C., Lawe, D. & Ziff, E.B. Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and Ras cotransformation. Cell 65, 395–407 (1991).
Ayer, D.E., Kretzner, L. & Eisenman, R.N. Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72, 211–222 (1993).
Zervos, A., Gyuris, J. & Brent, R., Mxil, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72, 223–232 (1993).
Blackwood, E.M., Luscher, B. & Eisenman, R.N. Myc and Max associate in vivo. Genes Dev. 6, 71–80 (1992).
Schreiber-Agus, N. et al. An amino-terminal domain of Mxil mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor Sin3. Cell 80, 777–786 (1995).
Ayer, D.E., Lawrence, A. & Eisenman, R.N. The amino-terminus of Mad mediates ternary complex formation with mammalian homologs of the yeast repressor Sin3 and is required for Mad:Max transcriptional repression. Cell 80, 767–776 (1995).
Amati, B. & Land, H. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr. Opin. Genet Dev. 4, 102–108 (1994).
Ayer, D. & Eisenman, R. A switch from Myc:Max to Mad:Max heterocomplexes accompanies macrophage differentiation. Genes Dev. 7, 2110–2119 (1993).
Larsson, L.-G., Pettersson, M., Oberg, F., Nilsson, K. & Luscher, B. Expression of mad, mxil, max and c-myc during induced differentiation of hematopoetic cells: Opposite regulation of mad and c-myc . Oncogene 9, 1247–1252 (1994).
Lahoz, E.G., Xu, L., Schreiber-Agus, N. & DePinho, R.A. Suppression of myc, but not E1 a, transformation activity by Max-associated proteins, Mad and Mxi1. Proc. natn. Acad. Set U.S.A. 91, 5503–5507 (1994).
Edelhoff, S. et al. Mapping of two genes encoding members of a distinct subfamily of Max interacting proteins: Mad to human chromosome 2 and mouse chromosome 6, and Mxil to human chromosome 10 and mouse chromosome 19. Oncogene 9, 665–668 (1994).
Gomez-Foix et al. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J. Biol. Chem. 267, 25169–25134 (1992).
Graham, F. & Prevec, L. Manipulation of adenovirus vectors. in Methods in Molecular Biology: Gene Transfer and Expression Protocols. (ed. Murray, E.) 109–128 (Humana Press, Inc., Jersey City, 1991).
Andrew, M. & Braciale, T. Antigen-dependent proliferation of cloned continuous lines of H-2-restricted influenza virus-specific cytotoxic T lymphocytes. J. Immun. 127, 1201–1207 (1981).
Philipp, A. et al. Repression of cyclin Dl: A novel function of myc . Molec. cell. Biol. 14, 4032–4043 (1994).
Kohl, N.E. et al. Selective inhibition of ras-dependent transformation by a far-nesyltransferase inhibitor. Science 260, 1934–1937 (1993).
Clayman, G. et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 55, 1–6 (1995).
Shindo, H., Tani, E., Matsumoto, T., Hashimoto, T. & Furuyama, J. Stabilization of c-myc protein in human glioma cells. Acta neuropath. 86, 345–352 (1993).
Evan, G.I. & Littlewood, T.D. The role of c-myc in cell growth. Curr. Opin. Genet. Dev. 3, 44–49 (1993).
Hunter, T. & Pines, J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79, 573–582 (1994).
Harrington, E., Fenidi, A. & Evan, G.I. Oncogenes and cell death. Curr. Opin. Genet. Dev. 4, 120–129 (1994).
Facchini, L., Chen, S. & Penn, L. Dysfunction of the myc-induced apoptosis mechanism accompanies c-myc activation in the tumorigenic L929 cell line. Cell Growth Dev. 5, 637–646 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chen, J., Willingham, T., Margraf, L. et al. Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells. Nat Med 1, 638–643 (1995). https://doi.org/10.1038/nm0795-638
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0795-638
This article is cited by
-
Oct-2 Transcription Factor Binding Activity and Expression Up-Regulation in Rat Cerebral Ischaemia is Associated with a Diminution of Neuronal Damage In Vitro
NeuroMolecular Medicine (2014)
-
Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome
International Journal of Hematology (2009)
-
Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network
British Journal of Cancer (2008)
-
Modelling Myc inhibition as a cancer therapy
Nature (2008)
-
c -MYC amplification and expression in astrocytic tumors
Acta Neuropathologica (2008)